Today, a Director at Iovance Biotherapeutics Inc (IOVA), Merrill A Mcpeak, bought shares of IOVA for $96.2K.
This is Mcpeak’s first transaction since reporting a Buy transaction on LLEX back in May 2015 This recent transaction increases Merrill A Mcpeak’s holding in the company by 2.24% to a total of $4.52 million.
See today’s analyst top recommended stocks >>
Currently, Iovance Biotherapeutics Inc has an average volume of 1.06M.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $26.25, reflecting a 171.2% upside. Starting in March 2018, IOVA received 34 Buy ratings in a row. Six different firms, including B.Riley FBR and Chardan Capital, currently also have a Buy rating on the stock.
Merrill A Mcpeak’s trades have generated a -22.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engagesin the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.
